General information
  • Disease category Other (BASEC)
  • Recruitment status recruitment completed (BASEC/ICTRP)
  • Trial sites
    Freiburg
    (BASEC)
  • Contact Abigail Calder abigail.calder@unifr.ch (BASEC)
  • Data Source(s) BASEC: Import from 03.04.2025 ICTRP: N/A
  • Last update 03.04.2025 07:20
HumRes55446 | SNCTP000004664 | BASEC2021-01322

Effects of LSD on Neuroplasticity in Healthy Individuals

  • Disease category Other (BASEC)
  • Recruitment status recruitment completed (BASEC/ICTRP)
  • Trial sites
    Freiburg
    (BASEC)
  • Contact Abigail Calder abigail.calder@unifr.ch (BASEC)
  • Data Source(s) BASEC: Import from 03.04.2025 ICTRP: N/A
  • Last update 03.04.2025 07:20

Summary description of the study

We want to investigate in this study whether treatment with LSD increases the neuroplasticity of the brain. Neuroplasticity is the brain's ability to form new connections and reorganize in response to new events. The results could be very important for the clinical development of new treatments for mental disorders. All healthy individuals can participate in the study if they meet the inclusion and exclusion criteria. Participation in the study involves a total of 8 laboratory visits, spread over at least 6 weeks. On two different dates, you will receive a dose of LSD ranging from 0 to 0.1 mg (100 micrograms). It will be randomly determined which dose you receive on which date. Neither you nor the study staff will know when you receive which dose (the study will therefore be conducted as

(BASEC)

Intervention under investigation

As part of the study, you will take LSD in an alcoholic liquid on two different days, between 0 and 0.1 mg (100 micrograms). There will be at least a one-month interval between these two dates.

(BASEC)

Disease under investigation

Healthy Participants

(BASEC)

Criteria for participation in trial
Physically and mentally healthy Aged between 21 and 55 years Right-handed (BASEC)

Exclusion criteria
Excessive substance use (including nicotine, alcohol, drugs, and medications) Personal or family history of psychotic disorders Arterial hypertension (BASEC)

Trial sites

Freiburg

(BASEC)

not available

Sponsor

Prof. Gregor Hasler

(BASEC)

Contact

Contact Person Switzerland

Abigail Calder

+41 26 304 26 05

abigail.calder@unifr.ch

University of Fribourg

(BASEC)

Scientific Information

not available

Name of the authorising ethics committee (for multicentre studies, only the lead committee)

Ethics Committee Bern

(BASEC)

Date of authorisation

08.11.2021

(BASEC)


ICTRP Trial ID
not available

Official title (approved by ethics committee)
Effects of Lysergic Acid Diethylamide (LSD) on Neuroplasticity in Healthy Human Subjects (BASEC)

Academic title
not available

Public title
not available

Disease under investigation
not available

Intervention under investigation
not available

Type of trial
not available

Trial design
not available

Inclusion/Exclusion criteria
not available

not available

Primary and secondary end points
not available

not available

Registration date
not available

Incorporation of the first participant
not available

Secondary sponsors
not available

Additional contacts
not available

Secondary trial IDs
not available

Results-Individual Participant Data (IPD)
not available

Further information on the trial
not available

Results of the trial

Results summary

not available

Link to the results in the primary register

not available